


PRODUCT INFORMATION



Dalcetrapib

Item No. 89450

CAS Registry No.: 211513-37-0
Formal Name: S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl]propanethioic acid, 2-methyl ester
Synonym: JTT-705
MF: C₂₃H₃₅NO₂S
FW: 389.6
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Dalcetrapib is supplied as a crystalline solid. A stock solution may be made by dissolving the dalcetrapib in an organic solvent purged with an inert gas. Dalcetrapib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of dalcetrapib in ethanol and DMF is approximately 30 mg/ml and approximately 20 mg/ml in DMSO.

Dalcetrapib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, dalcetrapib should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Dalcetrapib has a solubility of approximately 1 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Cholesteryl ester transfer protein (CETP) is an exchange protein which transfers cholesteryl esters from HDL to VLDL, IDL, and LDL in exchange for triglycerides.^{1,2} Dalcetrapib is an inhibitor of CETP that exhibits an IC₅₀ value of 9 μM for plasma CETP in rabbits.³ Inhibition of CETP by dalcetrapib in rabbits given an atherogenic diet leads to elevation of HDL, decreased VLDL, and attenuation of the induced atherosclerosis.³ In human subjects, dalcetrapib also inhibits CETP activity and increases plasma HDL levels but it does not reduce the risk of recurrent cardiovascular events.^{2,4}

References

1. Le Goff, W., Guerin, M., and Chapman, M.J. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. *Pharmacol. Ther.* **101**, 17-38 (2004).
2. Rader, D.J. Molecular regulation of HDL metabolism and function: Implications for novel therapies. *J. Clin. Invest.* **116**(12), 3090-3100 (2006).
3. Okamoto, H., Yonemori, F., Wakitani, K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. *Nature* **406**, 203-206 (2000).
4. Schwartz, G.G., Olsson, A.G., Abt, M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *New England Journal of Medicine* **367**(22), 2089-2099 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM